{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:51:50Z","timestamp":1789944710253,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.psychres.2007.09.010","type":"journal-article","created":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T12:29:29Z","timestamp":1226492969000},"page":"275-283","source":"Crossref","is-referenced-by-count":26,"title":["Correlates of response to Olanzapine in a North Indian Schizophrenia sample"],"prefix":"10.1016","volume":"161","author":[{"given":"Pramod","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhuti","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwajit L.","family":"Nimgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.","family":"Thelma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita N.","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2007.09.010_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-6-8","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib3","article-title":"Olanzapine in the treatment of schizophrenia: an open label comparative clinical label trial from North India","volume":"43","author":"Avasthi","year":"2001","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib4","series-title":"Presented at the 32th annual meeting of the American College of Neuropsychopharmacology Hawaii","article-title":"Olanzapine: a potential \u2018atypical\u2019 antipsychotic agent","author":"Beasley","year":"1993"},{"key":"10.1016\/j.psychres.2007.09.010_bib5","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1176\/appi.ajp.161.10.1798","article-title":"Interaction of COMT (Val(108\/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia","volume":"161","author":"Bertolino","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/jmg.29.12.858","article-title":"Association between schizophrenia and homozygosity at the dopamine D3 receptor gene","volume":"29","author":"Crocq","year":"1992","journal-title":"Journal of Medical Genetetics"},{"key":"10.1016\/j.psychres.2007.09.010_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.tpj.6500342","article-title":"Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies","volume":"6","author":"Davies","year":"2006","journal-title":"Pharmacogenomics Journal"},{"key":"10.1016\/j.psychres.2007.09.010_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00127-004-0749-1","article-title":"Evaluation of familial influences on the course and severity of schizophrenia among US and Indian cases","volume":"39","author":"Deshpande","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1016\/j.psychres.2007.09.010_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.schbul.a033343","article-title":"A Hindi version of the Diagnostic Interview for Genetic Studies","volume":"24","author":"Deshpande","year":"1998","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2007.09.010_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4088\/JCP.v65n0305","article-title":"Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol","volume":"65","author":"Dossenbach","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib12","first-page":"109","article-title":"5-HT2A receptor promoter polymorphism,-1438G\/A and negative symptom response to olanzapine in schizophrenia","volume":"37","author":"Ellingrod","year":"2003","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.psychres.2007.09.010_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajmg.b.20169","article-title":"Weight gain associated with the\u2212759C\/T polymorphism of the 5HT2C receptor and olanzapine","volume":"134","author":"Ellingrod","year":"2005","journal-title":"American Journal of Medical Genetics: B Neuropsychiatric Genetetics"},{"key":"10.1016\/j.psychres.2007.09.010_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00007691-200312000-00006","article-title":"Investigation of target plasma concentration\u2013effect relationships for olanzapine in schizophrenia","volume":"25","author":"Fellows","year":"2003","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.psychres.2007.09.010_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2006.06.021","article-title":"Olanzapine and haloperidol in first episode psychosis: two-year data","volume":"86","author":"Green","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2007.09.010_bib16","first-page":"660","article-title":"Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics","volume":"103","author":"Guha","year":"2005","journal-title":"Journal of the Indian Medical Associatrion"},{"key":"10.1016\/j.psychres.2007.09.010_bib17","series-title":"Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.psychres.2007.09.010_bib18","doi-asserted-by":"crossref","first-page":"32442","DOI":"10.1074\/jbc.M502563200","article-title":"Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2","volume":"280","author":"Hata","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.psychres.2007.09.010_bib20","first-page":"270","article-title":"The characteristics and application of new antipsychotic drugs","volume":"15","author":"Ishigooka","year":"2004","journal-title":"Japan Medical Association Journal"},{"key":"10.1016\/j.psychres.2007.09.010_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2007.09.010_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10401230309085687","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bmj.325.7358.243","article-title":"Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study","volume":"325","author":"Koro","year":"2002","journal-title":"British Medical Journal"},{"key":"10.1016\/j.psychres.2007.09.010_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/j.1326-5377.2004.tb06443.x","article-title":"Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement","volume":"181","author":"Lambert","year":"2004","journal-title":"Medical Journal of Australia"},{"key":"10.1016\/j.psychres.2007.09.010_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajmg.10200","article-title":"Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects","volume":"114","author":"Li","year":"2002","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.psychres.2007.09.010_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)37099-5","article-title":"Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs","volume":"283","author":"Lidow","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.psychres.2007.09.010_bib27","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.psychres.2007.09.010_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0893-133X(95)00150-C","article-title":"Dopamine receptor mRNA expression in human striatum and neocortex","volume":"15","author":"Meador-Woodruff","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2007.09.010_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/npp.1994.27","article-title":"Dopamine receptor gene expression in the human medial temporal lobe","volume":"10","author":"Meador-Woodruff","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2007.09.010_bib32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archpsyc.1997.01830240045007","article-title":"Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia","volume":"54","author":"Meador-Woodruff","year":"1997","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002130000639","article-title":"Insulin and leptin levels in patients with schizophrenia or related psychoses\u2014a comparison between different antipsychotic agents","volume":"154","author":"Melkersson","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2007.09.010_bib34","first-page":"37","article-title":"The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia","volume":"100","author":"Morozova","year":"2000","journal-title":"Zhurnal Nevrologi i Psikhiatri Imeni S S Korsakova"},{"key":"10.1016\/j.psychres.2007.09.010_bib36","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archpsyc.1994.03950110009002","article-title":"Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative","volume":"51","author":"Nurnberger","year":"1994","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0704786","article-title":"Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy","volume":"136","author":"Ortells","year":"2002","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.psychres.2007.09.010_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4088\/JCP.v60n1109","article-title":"Olanzapine increases weight and serum triglyceride levels","volume":"60","author":"Osser","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2007.09.010_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2007.05.036","article-title":"Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients","volume":"95","author":"Saddichha","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2007.09.010_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.HYP.36.2.183","article-title":"Dopamine D1 receptor gene polymorphism is associated with essential hypertension","volume":"36","author":"Sato","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.psychres.2007.09.010_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/(SICI)1096-8628(19991215)88:6<705::AID-AJMG22>3.0.CO;2-F","article-title":"Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4)","volume":"88","author":"Seaman","year":"1999","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.psychres.2007.09.010_bib42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine","volume":"156","author":"Seeman","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2007.09.010_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.psychres.2007.09.010_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.fpc.0000184957.98150.0f","article-title":"Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms","volume":"16","author":"Srivastava","year":"2006","journal-title":"Pharmacogenetic Genomics"},{"key":"10.1016\/j.psychres.2007.09.010_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0169-328X(97)00285-4","article-title":"Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain","volume":"53","author":"Stefanis","year":"1998","journal-title":"Brain Research: Molecular Brain Research"},{"key":"10.1016\/j.psychres.2007.09.010_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.20045","article-title":"Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia","volume":"124","author":"Szekeres","year":"2004","journal-title":"American Journal of Medical Genetics: B. Neuropsychiatric Genetics"},{"key":"10.1016\/j.psychres.2007.09.010_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.schres.2004.12.011","article-title":"Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms","volume":"75","author":"Tiwari","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2007.09.010_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.tpj.6500282","article-title":"Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism","volume":"5","author":"Tiwari","year":"2005","journal-title":"Pharmacogenomics Journal"},{"key":"10.1016\/j.psychres.2007.09.010_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/358149a0","article-title":"Multiple dopamine D4 receptor variants in the human population","volume":"358","author":"van Tol","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.psychres.2007.09.010_bib52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/hmg\/2.3.338","article-title":"An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis","volume":"2","author":"Warren","year":"1993","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.psychres.2007.09.010_bib53","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"63","author":"Wirshing","year":"2002","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178107003356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178107003356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T18:07:46Z","timestamp":1738519666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178107003356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0165178107003356"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2007.09.010","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}